Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 140

Sort by

Sort Order Select

Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2019) 134 (Supplement_1): 2865.

https://doi.org/10.1182/blood-2019-130633

Published: 2019

Journal Articles

Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia

Shadi Swaidani, MD PhD, Suman Kundu, MBA, Mohamed Samour, MBBS, Bernard Silver, MD, Joseph Parambil, MD, Sonia Thomas, DrPH, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 5761.

https://doi.org/10.1182/blood-2019-127344

Published: 2019

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia

Alina Rudorf, Tony Andreas Müller, Cathrin Klingeberg, Stefanie Kreutmair, Teresa Poggio, Sivahari Prasad Gorantla, Tamina Rückert, Annette Schmitt-Graeff, Anina Gengenbacher, Peter Paschka, Claudia Baldus, Robert Zeiser, George S. Vassiliou, Allan Bradley, Justus Duyster, Anna Lena Illert

Blood (2019) 134 (4): 383–388.

https://doi.org/10.1182/blood.2018883140

Published: 2019

Includes: Supplemental data

Journal Articles

Potential Predictors of Induction Failure and Complete Remission Duration in FLT3 -ITD Mutated Acute Myeloid Leukemia

Fevzi Yalniz, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Marina Y. Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MD MSc, Prithviraj Bose, MD, Michael Andreeff, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3996.

https://doi.org/10.1182/blood-2018-99-119928

Published: 2018

Journal Articles

Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies

Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Timothy A. Graubert, MD, Cyril H Benes, Gabriel Daniel Duda, DMD, PhD, Yi-Bin Chen, MD

Blood (2017) 130 (Supplement 1): 2643.

https://doi.org/10.1182/blood.V130.Suppl_1.2643.2643

Published: 2017

Journal Articles

Midostaurin Reduces Regulatory T Cell Population in Healthy and Acute Myeloid Leukemia Cells

Lucas Gutierrez, BS, Tian Zhang, BS, Miran Jang, PhD, Mojtaba Akhtari, MD, Houda Alachkar, PharmD, PhD

Blood (2017) 130 (Supplement 1): 2621.

https://doi.org/10.1182/blood.V130.Suppl_1.2621.2621

Published: 2017

Journal Articles

Improved Sensitivity in Detection of FMS-like Tyrosine Kinase Internal Tandem Duplication of a Method Using Next-Generation Sequencing Data

Junghoon Shin, MD, Daeyoon Kim, MS, Yoojin Hong, Youngil Koh, MD PhD, Hongseok Yun, Dong-Yeop Shin, MD PhD, Sung-Soo Yoon, MD PhD, Inho Kim, Junglim Lee, MD, Byung-Su Kim, MD PhD

Blood (2016) 128 (22): 2844.

https://doi.org/10.1182/blood.V128.22.2844.2844

Published: 2016

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Waleed Abdelall, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Keyur P. Patel, MD PhD, Elias J. Jabbour, MD, Naval G. Daver, MD, Tapan Kadia, MD, Rosilyn A. Gborogen, RN, Marina Konopleva, MD PhD, Farhad Ravandi, MD, Michael Andreef, MD PhD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1642.

https://doi.org/10.1182/blood.V128.22.1642.1642

Published: 2016

Journal Articles

A Novel Dual Class III/Src Family Tyrosine Kinase Inhibitor Is Highly Active Against FLT3-ITD Leukemia Cells In Vivo

Tereza Radosova Muchova, Eva Reznickova, Zuzana Somikova, Tomas Gucky, Miroslav Strnad, DSc, Vladimir Krystof, PhD, Vladimir Divoky, PhD

Blood (2016) 128 (22): 1569.

https://doi.org/10.1182/blood.V128.22.1569.1569

Published: 2016

Journal Articles

The 70-KDa Heat Shock Protein Surface Plasmon Resonance Biosensor for Examination of Blood Plasma Proteome in Myelodysplastic Syndromes Subgroups

Ondrej Pastva, MSc, Leona Chrastinova, PhD, MSc., Marketa Bockova, MSc, Pavel Sacha, PhD, MSc., Jiri Suttnar, PhD, MSc., Roman Kotlin, PhD, MSc., Alzbeta Hlavackova, PhD, MSc., Jaroslav Cermak, MD PhD, Jiri Homola, prof., PhD, MSc., DSc., Jan E. Dyr, prof., PhD, MSc., DSc.

Blood (2016) 128 (22): 5521.

https://doi.org/10.1182/blood.V128.22.5521.5521

Published: 2016

Journal Articles

Targeting the NRF2/HO-1 Antioxidant Pathway with Consequences for Notch Signaling in FLT3-ITD Positive AML: A Novel Therapeutic Approach

Marisa J Hornbaker, B.S., Mary E Irwin, PhD, LaNisha Patterson, B.S., Shelley M Herbrich, MS, Patrick Zweidler-McKay, MD PhD, Joya Chandra, PhD

Blood (2015) 126 (23): 2470.

https://doi.org/10.1182/blood.V126.23.2470.2470

Published: 2015

Journal Articles

Natural Killer Cells Contribute to Pathophysiology of Placenta Leading to Miscarriage in Fetal and Neonatal Alloimmune Thrombocytopenia

Issaka Yougbare, PhD, Tai Wei-she, Bsc, Darko Zdravic, MSc, Pingguo Chen, MD PhD, Guangheng Zhu, MD, Howard Leong-Poi, MD, Qu Dawei, PhD, X. Lisa Yu, MD, S. Adamson Lee, PhD, John Sled, PhD, Freedman John, MD, Heyu Ni, MD PhD

Blood (2015) 126 (23): 2254.

https://doi.org/10.1182/blood.V126.23.2254.2254

Published: 2015

Journal Articles

Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Harinder Gill, MD MBBS, MRCP, FRCP, FHKAM (MDcine), Albert Kwok Wai Lie, MD, Yok Lam Kwong, MD, Anskar Y.H. Leung, MD

Blood (2015) 126 (23): 5476.

https://doi.org/10.1182/blood.V126.23.5476.5476

Published: 2015

Journal Articles

The Role of Tumor Associated Macrophages in Multiple Myeloma and Its Pathophysiological Effect on Myeloma Cells Survival, Apopotosis and Angiogenesis

Yu Wu, MD PhD, Xinyi Chen, Yuhuan Zheng

Blood (2015) 126 (23): 4204.

https://doi.org/10.1182/blood.V126.23.4204.4204

Published: 2015

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Gautam Borthakur, MD, Hagop M. Kantarjian, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Naval Daver, MD, Tapan M. Kadia, MD, Rosilyn Gborogen, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 388.

https://doi.org/10.1182/blood.V124.21.388.388

Published: 2014

Journal Articles

The Senescence-Associated Secretory Phenotype In Multiple Myeloma

Tanya M Wildes, MD, MSCI, Jacob Paasch, BS, Mark A. Fiala, BS, CCRP, Ling Chen, PhD, Ravi Vij, MD, Keith E. Stockerl-Goldstein, MD, Sheila Stewart, PhD, Graham A. Colditz, MD, DrPH, Michael Tomasson, MD

Blood (2013) 122 (21): 5357.

https://doi.org/10.1182/blood.V122.21.5357.5357

Published: 2013

Journal Articles

STUDY ON ANTIANGIOGENENIC EFFECT OF ACANTHOPANAX SENTICOSUS IN HL60 CELL LINES

Chen Fangyuan, Sr., M.D, Zhang Minyue, Sr., M.D, Cai Jiayi, Sr., M.D, Shen Lijing, Sr., M.D

Blood (2013) 122 (21): 4857.

https://doi.org/10.1182/blood.V122.21.4857.4857

Published: 2013

Journal Articles

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

Elie Traer, MD, PhD, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer B Dunlap, MD, Isabel English, Jacqueline Martinez, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker

Blood (2013) 122 (21): 2541.

https://doi.org/10.1182/blood.V122.21.2541.2541

Published: 2013

Journal Articles

The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia

Krzysztof Giannopoulos, MD, PhD, Malgorzata Zajac, Anna Dolnik, Stephany Correa, Konstanze Dohner, Richard F. Schlenk, MD, Lars Bullinger, MD, PhD

Blood (2013) 122 (21): 2563.

https://doi.org/10.1182/blood.V122.21.2563.2563

Published: 2013

NARROW

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia

Potential Predictors of Induction Failure and Complete Remission Duration in FLT3 -ITD Mutated Acute Myeloid Leukemia

Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies

Midostaurin Reduces Regulatory T Cell Population in Healthy and Acute Myeloid Leukemia Cells

Improved Sensitivity in Detection of FMS-like Tyrosine Kinase Internal Tandem Duplication of a Method Using Next-Generation Sequencing Data

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

A Novel Dual Class III/Src Family Tyrosine Kinase Inhibitor Is Highly Active Against FLT3-ITD Leukemia Cells In Vivo

The 70-KDa Heat Shock Protein Surface Plasmon Resonance Biosensor for Examination of Blood Plasma Proteome in Myelodysplastic Syndromes Subgroups

Targeting the NRF2/HO-1 Antioxidant Pathway with Consequences for Notch Signaling in FLT3-ITD Positive AML: A Novel Therapeutic Approach

Natural Killer Cells Contribute to Pathophysiology of Placenta Leading to Miscarriage in Fetal and Neonatal Alloimmune Thrombocytopenia

Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

The Role of Tumor Associated Macrophages in Multiple Myeloma and Its Pathophysiological Effect on Myeloma Cells Survival, Apopotosis and Angiogenesis

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

The Senescence-Associated Secretory Phenotype In Multiple Myeloma

STUDY ON ANTIANGIOGENENIC EFFECT OF ACANTHOPANAX SENTICOSUS IN HL60 CELL LINES

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only